Literature DB >> 18971369

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.

Samih H Nasr1, Anthony M Valeri, Gerald B Appel, Julius Sherwinter, Michael B Stokes, Samar M Said, Glen S Markowitz, Vivette D D'Agati.   

Abstract

BACKGROUND AND OBJECTIVES: Dense deposit disease (DDD) is a rare disorder that most commonly affects children. This study reports the largest North American series addressing clinicopathologic and outcome differences in children and adults. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Thirty-two patients with DDD were analyzed from the archives of Columbia University between 1977 and 2007. Characteristic intramembranous electron-dense deposits defined all diagnoses.
RESULTS: The cohort included 14 children (<16 yr) and 18 adults, with 39% of adults >60 yr. The female/male ratio was 1.9. At presentation, the mean 24-h urine protein was 4.6 g, nephrotic syndrome was present in 33%, renal insufficiency in 59%, and hematuria in 87% of patients. Compared with adults, children had lower incidence of renal insufficiency and were more likely to have reduced C3. Histologic pattern included membranoproliferative, mesangial, endocapillary, and crescentic glomerulonephritis. Treatment included immunosuppression (IS) alone in seven, renin angiotensin system (RAS) blockade alone in six, and combined IS/RAS blockade in 11. On follow-up (mean 63 mo) available in 27 patients, 26% had complete response, 48% had persistent renal dysfunction, and 26% had ESRD. Correlates of ESRD were older age and higher creatinine at biopsy, the absence of combined IS/RAS blockade therapy and the presence of subepithelial humps, but not histologic pattern. On multivariate analysis, age and creatinine emerged as the only independent predictors of ESRD.
CONCLUSIONS: DDD is clinically and pathologically heterogeneous. Adults have worse outcome than children, despite similar treatment. Combined IS/RAS blockade appears superior to either agent alone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971369      PMCID: PMC2615696          DOI: 10.2215/CJN.03480708

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  21 in total

1.  Electron dense alteration of kidney basement membranes. A renal lesion specific of a systemic disease.

Authors:  P Galle; P Mahieu
Journal:  Am J Med       Date:  1975-06       Impact factor: 4.965

2.  Characteristics of a benign subtype of dense deposit disease: comparison with the progressive form of this disease.

Authors:  M Klein; S Poucell; G S Arbus; M McGraw; C P Rance; S J Yoon; R Baumal
Journal:  Clin Nephrol       Date:  1983-10       Impact factor: 0.975

3.  Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children.

Authors:  A E Davis; E E Schneeberger; W E Grupe; R T McCluskey
Journal:  Clin Nephrol       Date:  1978-05       Impact factor: 0.975

Review 4.  Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Br J Haematol       Date:  2007-12       Impact factor: 6.998

5.  Dense intramembranous deposit disease: new pathologic features.

Authors:  R K Sibley; Y Kim
Journal:  Kidney Int       Date:  1984-04       Impact factor: 10.612

6.  Mesangiocapillary glomerulonephritis: a long-term study of 40 cases.

Authors:  C P Swainson; J S Robson; D Thomson; M K MacDonald
Journal:  J Pathol       Date:  1983-12       Impact factor: 7.996

7.  Dense deposit disease in children: prognostic value of clinical and pathologic indicators. The Southwest Pediatric Nephrology Study Group.

Authors: 
Journal:  Am J Kidney Dis       Date:  1985-09       Impact factor: 8.860

Review 8.  Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis.

Authors:  J S Cameron; D R Turner; J Heaton; D G Williams; C S Ogg; C Chantler; G B Haycock; J Hicks
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

9.  Regression of membranoproliferative glomerulonephritis type II (dense deposit disease): observations in six children.

Authors:  P T McEnery; A J McAdams
Journal:  Am J Kidney Dis       Date:  1988-08       Impact factor: 8.860

10.  Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease.

Authors:  W M Bennett; R G Fassett; R G Walker; K F Fairley; A J d'Apice; P Kincaid-Smith
Journal:  Am J Kidney Dis       Date:  1989-06       Impact factor: 8.860

View more
  64 in total

1.  Eculizumab for dense deposit disease and C3 glomerulonephritis.

Authors:  Andrew S Bomback; Richard J Smith; Gaetano R Barile; Yuzhou Zhang; Eliot C Heher; Leal Herlitz; M Barry Stokes; Glen S Markowitz; Vivette D D'Agati; Pietro A Canetta; Jai Radhakrishnan; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

Review 2.  C3 glomerulopathy: a new classification.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi; Laure-Hélène Noël; H Terence Cook; Matthew C Pickering
Journal:  Nat Rev Nephrol       Date:  2010-07-06       Impact factor: 28.314

3.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

4.  Eculizumab in Pediatric Dense Deposit Disease.

Authors:  Michiel J S Oosterveld; Mark R Garrelfs; Bernd Hoppe; Sandrine Florquin; Joris J T H Roelofs; L P van den Heuvel; Kerstin Amann; Jean-Claude Davin; Antonia H M Bouts; Pietrik J Schriemer; Jaap W Groothoff
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-27       Impact factor: 8.237

5.  A case of regression of atypical dense deposit disease without C3 deposition in a child.

Authors:  Min Sun Kim; Pyoung Han Hwang; Mung Jae Kang; Dae-Yeol Lee
Journal:  Korean J Pediatr       Date:  2010-07-31

6.  Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Authors:  Valérie Leroy; Véronique Fremeaux-Bacchi; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes; Marie-Alice Macher; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2010-12-25       Impact factor: 3.714

7.  American Society of Nephrology clinical pathological conference.

Authors:  Kevin E Meyers; Helen Liapis; Mohamed G Atta
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 8.237

Review 8.  The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Authors:  Sanjeev Sethi; S Vincent Rajkumar; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2018-04-27       Impact factor: 10.121

9.  C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; Sanjeev Sethi
Journal:  Kidney Int       Date:  2018-05-03       Impact factor: 10.612

10.  C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; An S De Vriese; Sanjeev Sethi
Journal:  Mayo Clin Proc       Date:  2018-08       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.